Medtronic plc reported its financial results for FY25, revealing a worldwide revenue of $33.537 billion and an adjusted revenue of $33.627 billion, marking a 3.6% increase as reported and a 4.9% rise on an organic basis. The organic revenue growth comparison excludes other revenue of $48 million in the current year and $221 million in the prior year, alongside a foreign currency translation impact of -$244 million on the remaining segments. The company's GAAP operating profit stood at $5.955 billion, with an operating margin of 17.8%, representing increases of 16% and 190 basis points, respectively. In the fourth quarter, Medtronic's non-GAAP net income was $2.080 billion, while the non-GAAP diluted EPS was reported at $1.62, showing increases of 8% and 11%, respectively. Notably, the Q4 non-GAAP diluted EPS included a -7 cent impact from foreign currency translation, with a constant currency basis increase of 16%. These results highlight Medtronic's solid performance and growth, despite the currency translation challenges. The company continues to focus on its strategic initiatives to drive further growth and operational efficiency in the medical technology industry.